On the heels of what was already a closely watched Dec. 2 ruling from the U.S. Court of Appeals for the Federal Circuit in Ariosa v. Sequenom, a team of Sheridan Ross attorneys representing longtime client Genetic Technologies Ltd. argued before a Federal Cicuit three-judge panel on Dec. 7 (Genetic Technologies Ltd. v. Merial LLC) in a case that may ultimately provide answers to significant biotech industry questions surrounding patent eligibility.
Sheridan Ross P.C., has represented Genetic Technologies for several years, including the successful defense of Genetic Technologies’ patents before the USPTO.
Law360 covered the hearing and filed this story…(subscription required).
Leave a Reply
You must be logged in to post a comment.